RNAC: Cartesian Therapeutics, Inc. Stock

by  •  • Comments Off on RNAC: Cartesian Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 312.18
Enterprise Value ($M) 99.57
Book Value ($M) -6.80
Book Value / Share -0.26
Price / Book -45.90
NCAV ($M) -225.20
NCAV / Share -8.69
Price / NCAV -1.39

Profitability (mra)
Return on Invested Capital (ROIC) -10.78
Return on Assets (ROA) -0.24
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 9.43
Current Ratio 9.43

Balance Sheet (mrq) ($M)
Current Assets 216.63
Assets 435.02
Liabilities 441.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 38.91
Operating Income -36.32
Net Income -77.42
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -23.67
Cash from Investing -8.74
Cash from Financing 168.43

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13G Jpmorgan Chase & Co 6.10
02-12 13G/A Fmr Llc 9.40 -11.00
01-15 13D/A Springer Timothy A 36.90
10-15 13D/A Kalayoglu Murat 19.90 42.95

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-25 14,988 40,402 37.10
2025-04-24 14,239 42,648 33.39
2025-04-23 14,700 43,995 33.41
2025-04-22 21,580 53,672 40.21

(click for more detail)

Similar Companies
RCKT – Rocket Pharmaceuticals, Inc. RLAY – Relay Therapeutics, Inc.
RNA – Avidity Biosciences, Inc. RYTM – Rhythm Pharmaceuticals, Inc.
SAGE – Sage Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io